Vaccines Market and Covid-19
Vaccine is one of the man-made biological sources to increase immunity. It prevents several infectious diseases (bacterial or viral or others) before the disease causes death or severe illness to early infants or adults or old aged people. Vaccines have saved millions of lives from diseases like polio, influenza, measles, hepatitis, rotaviruses, DPT3 (Diphtheria, Pertussis, and Tetanus), etc. Few vaccines are required at regular intervals as boosters to maintain immunity against pathogens.
In the last few months, the coronavirus has impacted millions of lives worldwide. More than 1.04 million have lost their lives due to the unavailability of medicines and vaccines. Currently, more than 190 vaccine candidates are working on the coronavirus vaccine, out of which 10 vaccine candidates are in their phase-3 of the vaccine clinical trial process (human trials with a large array of people with different age groups, ethnicity, geography). As of 2nd Oct, 2020, WHO has released the updated draft landscape of COVID-19 candidate vaccines (click here to see the full details). Even the WHO is hoping to have the successful vaccine by the end of 2020 or early in 2021. As the covid-19 has caused the blockage of transportation for several months and financial distress among different groups of mid-scale and small-scale businesses, the successful coronavirus vaccine will be a remarkable opportunity for vaccine manufacturers in the next few years until the world gets free of the coronavirus.
The governments of many countries, WHO, and other associations & institutes are supporting the cause of manufacturing vaccines for covid19. Several governments, such as Japan, Australia, etc., have also announced to provide the coronavirus vaccine free of cost to their public once it is available in the future. They have entered into agreements with different vaccine candidates to secure millions of doses in advance. However, the covid-19 has also caused a slow down or halt of the vaccine supply & demand for other infectious diseases in 2020.
Vaccines are of different types including Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Conjugate vaccine, Toxoid Vaccines, Recombinant vector Vaccine, and DNA Vaccines. The increased growth in the vaccines market in the last few years is due to focus on growing infectious diseases, innovative healthcare technology, increased funding from governments, institutes, and international organizations & associations, and increasing awareness among the public. WHO has set Immunization Agenda 2030 with a global vision and strategies for vaccines and immunization for the period 2021-2030. Other organizations like UNICEF, NGOs, GAVI, Immunization Action Coalition (IAC), etc., are also supporting and promoting awareness to improve immunity and helping poor countries with vaccination programs against several diseases.
North America accounts for the largest market share in the vaccines market by region. However, Asia-pacific is the fastest growing market because of the higher population growth, increasing income level, and increased awareness about multiple diseases and their effects. One of the factors which may restraint the market is the cost of the vaccine. In the last few years, the cost of many vaccines has increased. However, government and humanitarian-aid-type buyers support relatively low vaccine prices. The growth in research facilities, laboratories, and new technologies in the healthcare industry has also supported the market’s continuous growth. Japan accounts for the highest market share in the Asia-pacific region, followed by China & India.
By disease indication type, bacterial disease types accounted for the largest market for vaccines over viral diseases. However, the market for vaccines of viral disease types is increasing at a faster growth rate. In bacterial disease types, pneumococcal disease type dominated the market, followed by meningococcal and DPT3. In viral disease type, influenza, hepatitis, and HPV has a significant growth rate and is estimated to have a CAGR of 8.34%, 7.36%, and 7.91% over the forecast period 2020-2025.
By age group, the pediatric vaccines market accounted for the highest market share (>58% in 2019) than the adults’ vaccines market because of the high birth rate and increased infant doses to prevent several diseases.
The market is highly competitive in top players, and also constant improvement in R&D and technologies supports approvals of new vaccines in the market. Authorities thoroughly test the novel vaccines during the pre-clinical trials and three different phases of vaccine trials. Some of the key players in the market include GlaxoSmithKline Plc (GSK), Novartis AG, Merck & Co., Inc., CSL Ltd, Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., AstraZeneca Plc, Abbott Laboratories, Inc., Serum Institute of India Pvt. Ltd., PT Bio Farma, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Sinovac Biotech Ltd, Valneva SE, VBI Vaccines Inc., Emergent BioSolutions, etc. among others.
Thank you for reading! Please share if you find it useful.